Shell Asset Management Co. Sells 9,445 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Shell Asset Management Co. reduced its stake in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Rating) by 12.9% in the 1st quarter, Holdings Channel reports. The firm owned 63,850 shares of the biotechnology company’s stock after selling 9,445 shares during the quarter. Shell Asset Management Co.’s holdings in Ironwood Pharmaceuticals were worth $803,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of IRWD. Advisor Group Holdings Inc. raised its position in shares of Ironwood Pharmaceuticals by 77.2% in the 4th quarter. Advisor Group Holdings Inc. now owns 14,432 shares of the biotechnology company’s stock worth $169,000 after acquiring an additional 6,289 shares in the last quarter. O Shaughnessy Asset Management LLC raised its position in shares of Ironwood Pharmaceuticals by 12.4% in the 4th quarter. O Shaughnessy Asset Management LLC now owns 19,852 shares of the biotechnology company’s stock worth $231,000 after acquiring an additional 2,195 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Ironwood Pharmaceuticals by 21.3% in the 4th quarter. Renaissance Technologies LLC now owns 2,679,253 shares of the biotechnology company’s stock worth $31,240,000 after acquiring an additional 469,700 shares in the last quarter. Gotham Asset Management LLC raised its position in shares of Ironwood Pharmaceuticals by 70.5% in the 4th quarter. Gotham Asset Management LLC now owns 187,652 shares of the biotechnology company’s stock worth $2,188,000 after acquiring an additional 77,582 shares in the last quarter. Finally, Inspire Investing LLC acquired a new stake in shares of Ironwood Pharmaceuticals in the 1st quarter valued at about $237,000.

Ironwood Pharmaceuticals Price Performance

IRWD stock opened at $11.45 on Monday. The company has a market capitalization of $1.76 billion, a P/E ratio of 3.59 and a beta of 1.09. The company has a debt-to-equity ratio of 0.76, a quick ratio of 4.82 and a current ratio of 4.82. Ironwood Pharmaceuticals, Inc. has a 52-week low of $10.13 and a 52-week high of $14.27. The business has a 50-day simple moving average of $11.63 and a two-hundred day simple moving average of $11.66.

Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Rating) last released its quarterly earnings results on Thursday, May 5th. The biotechnology company reported $0.21 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.27 by ($0.06). The company had revenue of $97.53 million for the quarter, compared to analyst estimates of $96.62 million. Ironwood Pharmaceuticals had a net margin of 124.83% and a return on equity of 34.67%. Ironwood Pharmaceuticals’s revenue for the quarter was up 9.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.24 EPS. Research analysts expect that Ironwood Pharmaceuticals, Inc. will post 1.17 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. StockNews.com upgraded Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, June 15th. Piper Sandler assumed coverage on Ironwood Pharmaceuticals in a research note on Friday, April 22nd. They issued an “overweight” rating and a $16.00 target price for the company.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other news, CEO Thomas A. Mccourt sold 19,959 shares of the business’s stock in a transaction that occurred on Thursday, June 30th. The stock was sold at an average price of $11.58, for a total value of $231,125.22. Following the transaction, the chief executive officer now owns 778,922 shares in the company, valued at approximately $9,019,916.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, Director Marla L. Kessler sold 7,610 shares of the business’s stock in a transaction that occurred on Tuesday, June 14th. The stock was sold at an average price of $11.65, for a total value of $88,656.50. Following the transaction, the director now owns 84,148 shares in the company, valued at approximately $980,324.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Thomas A. Mccourt sold 19,959 shares of the business’s stock in a transaction that occurred on Thursday, June 30th. The stock was sold at an average price of $11.58, for a total value of $231,125.22. Following the completion of the transaction, the chief executive officer now owns 778,922 shares in the company, valued at approximately $9,019,916.76. The disclosure for this sale can be found here. In the last quarter, insiders sold 254,260 shares of company stock worth $3,023,824. Insiders own 13.10% of the company’s stock.

About Ironwood Pharmaceuticals

(Get Rating)

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union.